3Richter J,Wagner U,Kononen J,et al.High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer[J].Am J Pathol,2000,157(3):787-794.
4Hoos A,Urist M J,Stojadinovic A,et al.Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors[J].Am J Pathol,2001,158(4):1247-1251.
5Hoos A,Cordon-Cardo C.Tissue microarray profiling of cancer specimens and cell lines:opportunities and limitations[J].Lab Invest,2001,81 (10):1331-1338.
6Nocito A,Bubendorf L,Tinner E M,et al.Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade[J].J Pathol,2001,194(3):349-357.
8Schraml P,Kononen J,Bubendof L,et al.Tissue microarrays for gene amplification surveys in many different tumor types[J].Clinical Cancer Res,1999,5 (7-9):1966-1972.
10Bubendof L,Kononen J,Koivisto P,et al.Survey of gene amplifications during prostate cancer progression by highthroughput fluorescence in hybridization on tissue microarrays[J].Cancer Res,1999,59 (4):803-806.
2Kononen J,Bubendorf L,Kallioniemi A,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens.Nat Med,1998,4:844--847.
3Bubendorf L, Kononen J, Koivisto P, et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays .Cancer Res ,1999,59:803-806.
4Moch H, Kononen J, Kallioniemi OP, et al. Tissue microarrays: what will they bring to molecular and anatomic pathology? Adv Anat Pathol, 2001, 8:14--20.
5Maxwell P, McCluggage WG. Audit and internal quality control in immunohistochemistry [ J ]. J Clin Pathol, 2000,53 ( 12 ) : 929 - 932.
6Rhodes A, Jasani B, Balaton AJ, et al.Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumors with that achieved on external quality assessment material in over 150 laboratories from 26 countries[J]. J CAin Pathol,2000,53(4) :292 - 301.
7Balaton A J, Mathieu MC, Le Doussal V. Optimization of heat-induced epitope retrieval for estrogen receptor determination by immunohistochemistry on paraffin sections: results of a multi-centric comparative study[ J ]. Appl Immunohistochem, 1996, 4 (4):259 -263.
8von Wasielewski R, Mengel M, Wiese B, et al. Tissue array technology for tetsting interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial[J]. Am J Clin Pathol,2002,118(5) :675 - 682.
5Matsushime H, Ewen M E, Strom D K, et al. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins[J]. Cell, 1992,71 (2) :323-334.
6Kawasaki H, Altieri D C, Lu C D, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer[ J]. Cancer Res, 1998,58(22) :5071-5074.
7Ikeguchi M, Ueda T, Sakatani T, et al. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma[ J ]. Diagn Mol Pathol, 2002,11 ( 1 ) :33-40.
8Suzuki A, Hayashida M, Ito T, et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16 (INK4a) and Cdk2/cyclin E complex activation[ J]. Oncugene, 2000,19 ( 29 ) : 3225-3234.
9Li F,Amhrosini G, Chu E Y, et al. Control of apoptosis and mitotic spindle checkpoint by survivin [ J]. Nature, 1998,396(6711 ) :580-584.
10Melief C J,Toes R E,Medema J P,et al.Strategies for immunotherapy of cancer[J].Adv Immunol,2000,75:235-282.
